1Research Scholar, SIRT-PHARMACY, Faculty of Pharmaceutical Sciences, Sanjeev Agrawal Global Educational University, Bhopal
2Professor, SIRT-PHARMACY, Faculty of Pharmaceutical Sciences, Sanjeev Agrawal Global Educational University, Bhopal
Rheumatoid arthritis (RA) is a progressive autoimmune disorder characterized by chronic joint inflammation, cartilage degradation, and elevated pro-inflammatory cytokines. The current study investigates the therapeutic potential of Nyctanthes arbor-tristis (NAT) using compiled secondary data from phytochemical, in-vitro, in-vivo, and in-silico studies. Analysis of existing literature revealed that NAT contains iridoid glycosides, flavonoids, phenolic acids, and terpenoids that contribute to its anti-inflammatory, antioxidant, and immunomodulatory properties. Animal-model evidence demonstrates significant reductions in paw edema (42–65%), suppression of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β, and enhancement of antioxidant enzymes such as SOD, catalase, and glutathione. Structural joint protection, including reduced synovial hyperplasia and preserved cartilage, further supports its therapeutic relevance. A comparison with conventional RA drugs indicates that while synthetic medications offer stronger immediate cytokine suppression, they are associated with adverse effects and high cost. NAT, however, provides a safer, multi-target, low-cost alternative suitable for long-term management. Overall, this review consolidates evidence supporting NAT as a promising adjunct or complementary therapeutic option in RA management.
Keywords: Nyctanthes arbor-tristis, Rheumatoid arthritis, Cytokine suppression, Anti-inflammatory, Antioxidant activity, Herbal therapeutics.
How to cite this article: Bhivshet G, Banweer J. Therapeutic potential of nycthantus Arbor tristis in the treatment of Rheumatoid Arthritis. Int J Drug Deliv Technol. 2026;16(12s): 186-191. DOI: 10.25258/ijddt.16.12s.20
Source of support: Nil.
Conflict of interest: None